Diamond Biofund (TPE:6901) YoY EBITDA Growth: 874.02% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6901 Diamond Biofund Inc TPE:6901
24 GF Score
Price NT$15.10
! 2 Warning Signs
View Full Analysis

What is Diamond Biofund YoY EBITDA Growth?

Diamond Biofund TPE:6901 +0.33% 24 YoY EBITDA Growth is 874.02% as of Jun. 2026. GuruFocus rates TPE:6901 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Diamond Biofund's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 874.02%.

Diamond Biofund's EBITDA per Share for the three months ended in Jun. 2026 was NT$3.96.

Diamond Biofund YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Diamond Biofund's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biofund YoY EBITDA Growth Chart

Diamond Biofund Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -51.29 -70.89 -386.06 15.86 51.76

Diamond Biofund Quarterly Data
Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -245.95 83.05 98.93 38.12 874.02
TPE:6901
24GF Score
Diamond Biofund Inc TPE:6901
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biofund YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Diamond Biofund's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-1.341--2.78)/ | -2.78 |
=51.76 %

Diamond Biofund's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(3.963--0.512)/ | -0.512 |
=874.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 874.02% mean?
Diamond Biofund (TPE:6901) has a YoY EBITDA Growth of 874.02% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Diamond Biofund and its competitors.
Is Diamond Biofund's YoY EBITDA Growth too high?
Diamond Biofund's current YoY EBITDA Growth is 874.02%. Overall, Diamond Biofund has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's YoY EBITDA Growth compare to BLK and BX?
Diamond Biofund's YoY EBITDA Growth of 874.02% can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for an Asset Management company?
A good YoY EBITDA Growth depends on the Asset Management industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Diamond Biofund and its competitors. Diamond Biofund's current YoY EBITDA Growth is 874.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current YoY EBITDA Growth of 874.02%. The current YoY EBITDA Growth is 874.02%. Diamond Biofund's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current YoY EBITDA Growth is 874.02% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diamond Biofund Business Description

Address Zhongxiao West Road, 34th Floor, No. 66, Section 1, Zhongzheng District, Taipei, TWN, 100
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
24GF Score

Get the complete analysis for TPE:6901

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.10
Price